Acerus Pharmaceuticals (ASPCF) Releases Earnings Results, Misses Estimates By $0.01 EPS

Acerus Pharmaceuticals (OTCMKTS:ASPCF) posted its earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.01), Morningstar.com reports. The firm had revenue of $2.17 million during the quarter.

Shares of ASPCF stock remained flat at $$0.12 during trading hours on Tuesday.

COPYRIGHT VIOLATION WARNING: “Acerus Pharmaceuticals (ASPCF) Releases Earnings Results, Misses Estimates By $0.01 EPS” was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.wkrb13.com/2019/05/14/acerus-pharmaceuticals-aspcf-releases-earnings-results-misses-estimates-by-0-01-eps.html.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.

See Also: Understanding the different types of bonds

Earnings History for Acerus Pharmaceuticals (OTCMKTS:ASPCF)

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.